A comparative study of the prevalence of hyperkalemia with the use of angiotensinconverting enzyme inhibitors versus angiotensin receptor blockers

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 547-552

  Sadjadi, Seyed Ali ^a   McMillan, James I ^a   Jaipaul, Navin ^a   Blakely, Patricia ^a   Hline, Su Su ^b  

^a Jerry L Pettis Memorial VA Medical Center   (United States)

^b LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Hyperkalemia

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CAPTOPRIL; CARBON DIOXIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; GLUCOSE; IRBESARTAN; LISINOPRIL; LOSARTAN;

AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PREVALENCE; RETROSPECTIVE STUDY; UNITED STATES; VETERAN;

EID: 77949472361     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007-2018.
2. Massie BM, Armstrong PW, Cleland JG, et al. Toleration of high doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure: Results from the Atlas trial. Arch Intern Med. 2001;161(2):165-171.
3. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. Randomized trial of the angiotensin receptor blocker, valsartan, in chronic heart failure. N Engl J Med. 2001;345(23):1667-1675.
4. Granger CB, Ertl G, Kuch J, et al. Randomized trial of candesartan in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin converting enzyme inhibitors. Am Heart J. 2000;139:609-617.
5. Blake J, Deverux RV. Differential effects of direct antagonism of AII receptor blockers compared to ACE inhibitors on serum potassium levels and azotemia in patients with severe congestive heart failure. Congestive Heart Fail. 2000;6:193-196.
6. Bakris G, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure. Kidney Int. 2000;58:2084-2092.
7. Preston RA, Baltodano NM, Alonso AB, Epstein M. Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type 2 diabetes mellitus. J Clin Pharmacol. 2002;42:754-761.
8. Packer M, Coats AJS, Fowler MB. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
9. Pitt B, Remm W, Zannad F, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
10. Pitt B, Remm W, Zannad F, et al. Eplerenone post acute myocardial infarction heart failure efficacy and survival study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
11. Ahmed A. American College of Cardiology/American Heart Association chronic heart failure evaluation and management guidelines: Relevance to the geriatric practice. Am J Geriatr Soc. 2003;51:123-126.
12. Lewis EJ, Hunsicker LG, Clark WR, et al; For Collaborative Study Group. Renoprotective effect of angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
13. Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW. Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol. 2009;4(4):820-829.
14. Nutahara K, Higashihara E, Horie S, et al. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract. 2005;99(1):18-23.
15. Kanno Y, Okada H, Yamaj i Y, Nakazato Y, Suzuki H. Angiotensin- converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation. QJM. 2005;98(3):199-203.
16. Li PK, Leung CB, Chow KM; For HKVIN Study Group. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind randomized, placebo-controlled study. Am J Kidney Dis. 2006; 47(5):751-760.
17. Taal M, Brenner B. Combination ACEI and ARB therapy: Additional benefit in renoprotection. Curr Opin Nephrol Hypertens. 2000;11:377-381.
18. Segura J, Praga M, Rodicio JL, Ruilope LM. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. J Renin Angiotensin Aldosterone Syst. 2003;4:43-47.
19. Dillon JL. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy. Semin Nephrol. 2004;24:218-224.
20. The ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
21. Knoll GA, Saghagal A, Nair RC, Grhahm J, et al. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med. 2002;112:110-114.
22. Fang J, Modhavan S, Cohen H, Alderman MH. Serum potassium and cardiovascular mortality. J Gen Intern Med. 2000;15:8850-890.
23. Charytan D, Goldfarb D. Indications for hospitalization of patients with hyperkalemia. Arch Intern Med. 2000;160:1605-1611.
24. Winkelmayer WC, Zhang Z, Shainfar S, et al. Efficacy and safety of angiotensin II receptor blockade in elederly patients with diabetes. Diabetes Care. 2006;29:2210-2217.
25. Appel GB, Radhkrishnan J, Avram M, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care. 2003;6:1402-1407.
26. Don BR, Sebastian A, Cheitlin M, Christiansen M, Schambelan M. Pseudohyperkalemia caused by fist clenching during phlebotomy. N Engl J Med. 1990;322:1290-1292.
27. Shlipak MG. Pharmacology of heart failure in patients with renal insufficiency. Ann Intern Med. 2003;138:917-924.
28. Heywood T, Fonarow G, Costanzo M, Mathur V, et al. High prevalence of renal dysfunction and its impact on outcome in 118465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE data base. J Card Fail. 2007;13:422-430.
29. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of randomized aldactone evaluation study. N Engl J Med. 2004;351:543-551.
30. Palmer BF. Current concepts: Managing hyperkalemia caused by inhibitors of the renin angiotensin aldosterone system. N Engl J Med. 2004;351:543-551.
31. Takaichi K, Takemoto F, Ubara Y, Mori Y. Analysis of factors causing hyperkalemia. Intern Med. 2007;46:823-829.
32. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. for the Valsartan in Acute Myocardial Infarction Trial Investigators: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;49:1893-1906.